Abstract
PURPOSE: To report the outcome of nasolacrimal duct balloon catheter dilation as the primary treatment of congenital nasolacrimal duct obstruction (NLDO) in children younger than 4 years of age.
METHODS: One hundred two children (151 eyes) ages 12 to <48 months (mean, 23 months) at the time of surgery, who previously had not undergone a nasolacrimal surgical procedure and who presented with at least one of the following clinical signs of NLDO--epiphora, increased tear lake, and/or mucous discharge--were enrolled in a prospective, nonrandomized observational multicenter study (20 sites). All children received balloon catheter dilation of the nasolacrimal system of the affected eye(s).
RESULTS: Treatment success was defined as no epiphora, increased tear lake, and/or mucous discharge present at the outcome visit at 1 month after surgery. The proportion of eyes treated successfully was 82% (95% CI: 74%-88%). The dye disappearance test at outcome was normal in 105 (73%), indeterminate in 15 (10%), and abnormal in 23 (16%) of the 143 eyes tested.
CONCLUSIONS: In children 12 to <48 months of age, balloon catheter dilation as a primary treatment of NLDO was successful in approximately 80% of cases. Because we did not perform a randomized trial with a comparison group, we were unable to determine how this procedure's success rate compares with that of simple probing or nasolacrimal intubation in this age group.
Original language | English (US) |
---|---|
Pages (from-to) | 451-5 |
Number of pages | 5 |
Journal | Journal of AAPOS |
Volume | 12 |
Issue number | 5 |
DOIs | |
State | Published - Oct 2008 |
Keywords
- Catheterization
- Child, Preschool
- Female
- Fluorescein/pharmacokinetics
- Fluorescent Dyes/pharmacokinetics
- Humans
- Infant
- Lacrimal Apparatus Diseases/etiology
- Lacrimal Duct Obstruction/complications
- Male
- Nasolacrimal Duct
- Prospective Studies
- Quality of Life
- Tears/metabolism
- Treatment Outcome
PubMed: MeSH publication types
- Journal Article
- Multicenter Study
- Research Support, N.I.H., Extramural